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Precise and Label-free Tumour Cell Recognition Based on A Black 
Phosphorus Nanoquenching Platform 
Wujuan Yana, Xiu-Hong Wang *a, Jingwen Yua, Xiaotong Menga, Pengfei Qiaoa , Huabing Yinb, 
Yongzhe Zhangc and Pu Wanga 
Breast cancer is a type of heterogeneous disease which manifests as different molecular subtypes due to the complex nature 
of tumour initiation, progression, and metastasis. Accurate idenfication of a breast cancer subtype plays crucial roles for 
breast cancer management. Herein, taking the advantages of efficient quenching properties of black phosphorus nanosheets 
(BPNSs), in combination with the high specificity of ssDNA (or RNA) aptamer, a fluorometric duplexed assay that is capable 
of simultaneous detection of two tumour markers within one run is developed. When mixed with BPNSs, the fluorescence 
of both FAM and Cy3 labelled aptamers was quenched. The presence of different subtypes of breast cancer cells restored 
the FAM and Cy3 fluoresecence at distinct pattern according to their intrisic features. The proposed assay can precisely 
recognise label-free breast cancer subtypes, providing an efficient way for cell type identification and guidance for 
subsequent breast cancer treatment. The significance of the proposed study is two-fold. First we provide a simple way for 
sensitive and specific tumour cell detection; secondly, the proposed dual assay allows precise recognization of tumour cells 
and  thus opens a door for rapid characterization and sorting of a wide range of tumours without using expensive 
instruments.
Introduction 
Breast cancer is the most commonly occurring cancer in 
women, comprising almost one third of all malignancies in females. 
Breast cancer is not just a single type of disease, but rather a variety 
of intricate subtypes which require different treatment strategies.1, 2 
For instance, some breast cancers grow in response to hormone 
stimuli while others not. These different subtypes could be 
characterized by their genetic profiles. Precise recognition of a breast 
cancer subtype could potentially allow more effective personalized 
treatment and plays vital roles for improving the cancer 
management.  
Nanomaterials have emerged as an effective stage for detecting 
biomedical molecules (DNA, peptide, glucose, cancer biomarkers 
etc.) or live pathological cells via various techniques.3-5 Fluorescent 
nanomaterials, such as quantum dots (Qdots) and fluorescent carbon 
nanoparticles etc., are especially prominent for detection in 
biomedical applications due to the high sensitivity and 
reproducibility. Rather than acting as a fluorophore, some 
nanomaterial-based probes have been exploited by using 
nanomaterials as fluorescent quenchers. For instance, gold 
nanoparticles (AuNPs) have been described as highly eﬃcient 
nanoquenchers. Functionalized with specially designed hair-pin 
structured aptamers, AuNPs were able to sense tumour-related 
proteins at high sensitivity.6 Graphene Oxide (GO) and transition 
metal dichalcogenides (TMDs, including MoS2, WS2 etc.) were 
reported as nanoquenchers via long-range energy transfer and 
related nanoprobes have been successfully developed via coupling 
with biomolecular recognition events for the ﬂuorometric detection 
of nucleic acids,7, 8 proteins,9 prostate cancer antigen (PSA),10 metal 
ions11, 12 and small molecules.8, 13-15  Despite of that, it was reported 
that AuNPs either adsorb DNA too tightly (e.g. >10–13 nm) or too 
weakly (e.g. 0-3 nm), binding induced disassociation has not been a 
popular signalling method.16 Whereas for GO, the surface is quite 
heterogeneous, displaying both hydrophobic regions favourable for 
DNA adsorption and highly oxidized regions that repel DNA. 
Biosensors based on DNA and surface interaction can be further 
improved via exploring new materials, improving the quench-
recovery response time, tuning the DNA-surface interactions etc. to 
achieve higher sensitivity, better speciﬁcity and faster response. It is 
in this context we initiated this study.  
Recently, black phosphorus (BP) has received enormous 
attention as a new 2D material. Although being a graphene analogue, 
some properties of BP even outperform those of graphene.17, 18  
 
Scheme 1. A schematic illustration of the fluorometric switch for 
specific breast cancer cell recognition via fluorescent quench and 
restoration. 
 
BP has a direct bandgap that is tuneable from 0.3 eV to 2.0 eV, which 
spans over the gap between graphene and 2D TMDs.19 Moreover, 
the excellent charge-carrier mobility (up to 1000 cm2·V−1·s−1), good 
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current on/oﬀ ratio (ca. 104−105) and a striking in-plane anisotropy 
of BP render this 2D material a perfect candidate for nanoelectronics 
and nanophotonics.20-23 BP nanomaterials also showed high 
biocompatibility and have been used in drug delivery, cancer therapy 
and photoacoustic imaging in biomedical area.24-26 Nevertheless, 
applications of BP nanomaterials in label-free pathological cell 
sensing have not been explored. 
Herein, we report that multi-layer black phosphorus 
nanosheets (BPNSs) functionalized with dual cell-recognizing 
aptamers can simultaneously and precisely recognize multiple 
subtypes of breast cancer cells. First, we demonstrate that 
BPNSs could quench the fluorescence of dye FAM. Subsequently 
we designed a probe via integrating BP and fluorescent 
aptamers. The proposed quench-and-recovery strategy is 
depicted in Scheme 1. Previously, the interaction of single 
strand DNA (ssDNA) with BP nanostructures has been examined 
experimentally.27-29 BP multi-layer adsorbs dye-labelled ssDNA 
(or RNA) aptamer via van der Waals force between nucleobases 
and the basal plane of phosphorene, then quench the 
ﬂuorescence of the dye. When the aptamer-BP complex is 
hybridized with target cells, the ssDNA aptamers recognize and 
interact with the cell, which disrupts the interaction previously 
formed between the ssDNA and multilayer BP. As a result, the 
dye-labelled probe is disassociated from BP, resulting in 
ﬂuorescence restoration. Therefore, the ﬂuorescence of the 
probe is expected to provide a quantitative readout of the 
target cell.  
A single aptamer would only recognize one specific episode 
on the cell, which sometimes could result in false results. 
Integrating two or more specific aptamers onto BPNSs would 
overcome the shortcoming and allow precise recognition of 
dual cell surface markers in a single run with improved 
diagnostic specificity. This is important since one kind of tumour 
cell may express a variety of tumour markers.30, 31 Such multi-
aptamer approaches would take full advantage of the 
capabilities of a cell-based therapy, as cells usually integrate 
multiple inputs to modulate their natural decisions in 
sophisticated ways. Moreover, the simultaneous dual-analysis 
of cancer biomarkers can simplify the analytical procedure, 
enhance the detection throughput, and decrease the detection 
cost.  
 
Results and discussion 
 
Fabrication and Characterization 
Bulk red phosphorus was transformed into micro-sized particles of 
BP via a high energy mechanical milling (HEMM) technique under 
ambient conditions.32 BPNSs were fabricated from the micro-sized 
BP powder using a modified liquid exfoliation method. The as-
exfoliated product was dispersed in ddH2O. High resolution 
transmission electron microscopy (HRTEM) was employed to 
examine the morphology of as-exfoliated materials. Fig 1a shows a 
typical HRTEM image of the fabricated BP products, in which each 
individual nanostructure shows a planar morphology. Statistical 
analysis of HRTEM image indicated that most of the BPNSs were in 
an average size of 55±25 nm, see the inset of Fig 1a. As shown in Fig 
1b, BPNSs have strong Raman-active stretching transitions at 
362.52cm-1, 439.33cm-1 and 466.59cm-1 which are attributed to Ag1, 
B2g, and Ag2 vibrational modes.18 Compared to bulk BP, the Ag1, B2g, 
and Ag2 modes of BPNSs were blue-shifted by 0, 2.28, 1.13cm-1, 
respectively. A similar blue shift has been observed for a few layers 
BPNSs and BP nanodots.33 Raman signals of layered BP were less 
intensified compared to the bulk BP, which is in agreement with 
previous reports.34 In an effort to elucidate the height of BPNSs, 
atomic force microscopy (AFM) imaging was performed at multiple 
locations across the sample. Due to resolution limitation of AFM, 
only larger size sheets were chosen for height measurement. The 
AFM topographic images in Fig 1c and d indicated the average height 
of BPNSs was 8±4 nm, corresponding to ~16±8 layers of 
phosphorene. 
 
 
Fig 1. Topographic characterization of BPNSs: (a) HRTEM image of as-
exfoliated products, inset shows the statistical results of 100 
nanostructures; (b) Raman spectra of bulked BP (black line) and as-
exfoliated BP nanostructures (blue line); (c) AFM image of a 
randomly selected region of an exfoliated sample;(d) Height 
distribution profile obtained from (c). 
 
BPNSs quenched the fluorescence of FAM 
Freshly prepared BPNSs were incubated with FAM.  Fig 2a 
shows the fluorescence in the presence or absence of BPNSs, 
striking decreases of fluorescence intensities in the presence of 
BPNSs were observed. The quenching efficiency was positively 
correlated with the concentration of BPNSs (Fig 2b). To further 
investigate the long-term quenching by BPNSs, we evaluated 
the fluorescence in the presence of BPNSs for 24h. Immediate 
quench was observed for FAM.  Maximum quench was quickly 
achieved and quenching efficiency remained unchanged for up 
to 24h (Fig 2c). Similarly, BPNSs also efficiently quenched the 
fluorescence of green fluorescent protein (GFP), Fig S1 (ESI†). 
The data clearly suggested that BPNSs had high quenching 
efficiency.  
 
Assessment of the fluorescence lifetime (FLT) could 
provide strong evidence for identifying the quenching 
dynamics. The FLTs of FAM in the presence or absence of BPNSs 
were thus measured. As shown in Fig S2 (a) (ESI†), the FLTs of 
FAM in every case was almost synchronous, indicating the 
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quenching process by BPNSs was static quenching. The fitting of 
Stern-Volmer plot also indicates the involvement of static 
quenching. (For more details please refer to ESI). This is 
different from the data of a just accepted manuscript,35 where 
both static and dynamic processes in the quenching of CsPbBr3 
QD photoluminescence by FLBP were demonstrated.  
When the FAM fluorescent emission peak was decreased, the 
photoluminescence emission of BPNSs (at 690 nm) was not 
intensified, suggesting that the quenching mechanism by BPNSs was 
not via non-radiative energy transfer, since a non-radiative energy 
transfer process is often featured by decreased donor emission with 
an associated increase of acceptor emission. Most likely, the high 
efficient quenching occurred through the light induced electron 
transfer from the photoexcited FAM to BPNSs.32 BPNSs have very 
strong adsorption capacity, can adsorb molecules on its surface 
via ionic bond, dispersion force, van der Waals force etc.29, 36, 37 
Moreover, large surface area provides a better platform for 
adsorption, which would allow the fluorophores to form 
complexes with BPNSs, hence reduced the population of active, 
excitable fluorophores, resulted in high quenching capability of 
BPNSs. 
 
 
Fig 2. Quenching ability of BPNSs. (a) Fluorescence spectra of 
FAM in the presence of different concentrations of BPNSs as 
indicated; (b) Quenching efficiency for FAM is positively 
correlated with BP concentration. (c) Stable quenching by 
BPNSs over time. CFAM =50fM, λex=470nm. 
 
 
 
 
Sensing intracellular estrogen receptor (ER) of breast 
cancer cells 
Breast cancers can be subtyped based on their molecular 
features, for instance hormone receptor positive (estrogen 
receptor positive (ER+) or progesterone receptor positive 
(PR+)), Her2-positive (Her2+), or triple negative (ER-, PR- and 
Her2-). Diagnosing the type of breast cancer is important for 
choosing the treatment approach since some medication is only 
efficient for one of these types. Approximately 70% of breast 
tumours are over expressing ER, referred to as ER+, and tumour 
cell proliferation is thought to be dependent on the activity of 
this hormone-mediated factor.  
Equipped with the quenching property of BPNSs, we were 
in a very good position to design nanoprobes for bio-sensing. 
We first explored to probe ER+ breast cancer cells using BPNSs 
platform functionalized with Cy3-AptER, a fluorescently labelled 
RNA aptamer, which can specifically recognize intracellular ER. 
Since the side chains of RNA would have strong interaction with 
BPNSs, as illustrated in scheme 1, BPNSs efficiently quenched 
the fluorescence of Cy3-AptER in a dose-dependent manner (Fig 
S3 (ESI†)).   
Then we examined a panel of breast cancer cells, including 
MCF7, T47D and MDA-MB-231, for their ability to restore the 
fluorescence. We chose a BP concentration which can quench 
90% of Cy3-AptER fluorescence (Fig 3a black line) as a start point 
for the following assays. As shown in Fig 3a and b, the presence 
of MCF7 cells markedly restored the fluorescence of Cy3. The 
restored fluorescence was positively dependent on the cell 
number (Fig 3b). Maximum recovery was achieved with 10000 
cells, by which 97.36% fluorescence was restored (Restoration 
ratio was calculated by equationηR=FR/F0, where FR and F0 are 
the fluorescence intensities in the presence of cells and pure 
Cy3-AptER, respectively), indicating the binding between AptER 
and ER receptor reached saturation. When cell number went 
down to as low as 250, around 63.17% of fluorescence was 
restored. Cell number lower than 250 failed to restore the 
fluorescence. The response time of the probe was very fast. 
Immediate fluorescence restoration was observed uopn 
addition of the probe. In order to obtain more reliable and 
reproducible data, the target cells were incubated with the 
probe for 30-120min before measuring. 
 
 
Fig 3. Fluorescence restoration by ER+ cells. (a) Fluorescence 
recovery in the presence of different numbers of MCF7 cells as 
indicated; (b) The dose-dependent relationship between MCF7, 
T47D cell number and recovered fluorescence; (c) Normalized 
recovered fluorescence intensity  of Cy3 in different type of cells 
(cell number=10000). CCy3-AptER=100nM, CBP=0.4mg/mL, 
λex=500nm. (d) T47D cells failed to recover the quenched 
fluorescence of Cy3 labelled on a random sequence DNA (Cy3-
R, 100nM). 
 
 
Similar to MCF7, T47D breast cancer cells also efficiently 
restored the fluorescence (Fig 3b red line and 3c aqua bar), the 
maximum restoration was around 75.1% with a cell number of 
10000.  The higher maximum fluorescence recovered by MCF7 
than T47D indicated the quantity of ER receptor in MCF7 cells 
was higher than that of T47D. Whereas MDA-MB-231 cells only 
restored 10% of the fluorescence with 10000 cells, which is 
much lower compared with MCF7 and T47D cells. The results 
were in good consistence with the published data that MCF7 
and T47D cells are ER+, while MDA-MB-231 cells are ER 
negative. A random RNA sequence labelled with Cy3 (Cy3-R) 
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was tested in parallel. The fluorescence of Cy3-R was also 
quenched efficiently by BPNSs (Fig 3d. black line); however, the 
fluorescence was not restored by either MCF7 or T47D cells (Fig 
3d, blue line), indicating the specificity of AptER 
. 
In our experiments, we observed excellent fluorescence 
restoration in the presence of target cells, indicating that both 
the function and specific secondary structure of AptER were 
well retained upon interaction with BPNSs.  
 
 
Fig 4. LSCM images of BPNSs/Cy3-AptER treated cells. Cells were 
incubated with BPNSs/Cy3-AptER nanoconstructs for 2h, then 
washed with PBS and imaged by LSCM. Cell number = 10000, 
CCy3-AptER=100nM, CBP=0.4mg/mL，λex=514nm. 
 
To confirm the results obtained from the 
spectrofluorometer, laser scanning confocal microscopic 
(LSCM) analysis was performed to further elucidate the 
aptamer-cell interaction and fluorescence recovery. As shown 
in Fig 4, after treated with BPNSs/Cy3-AptER complex, the 
majority of MCF7 cells were stained with Cy3, the nuclei were 
particularly heavily stained since ERs were more recognized as 
a nuclear receptor. T47D cells were stained both on the cell 
membrane and in the nuclei. Whereas few MDA-MB-231 cells 
were stained. The imaging results were in good consistence with 
the fluorometric data.  
Sensing cell surface marker MUC1  
 
Similar to the experiment above, we replaced the Cy3-
AptER aptamer with FAM-AptM, a FAM labelled ssDNA aptamer 
that can recognize a specific surface marker MUC1 of MCF7 
cells. The fluorescence of FAM-AptM was efficiently quenched 
by BPNSs in a dose dependent manner (Fig S4 (ESI†)).  
 
In the presence of different numbers of MCF7 cells (0, 100, 
250, 500, 1000, 2500, 5000, 8000, 10000, 15000, 20000), a 
striking cell number-dependent restoration of the FAM 
fluorescence was observed (Fig 5a, b). Maximum recovery was 
achieved with 15000 cells, the recovery rate was 106.67% (Fig 
5b). In the range of 0-2000 cells, there was a linear relationship, as 
shown in figure 5b inset. The limit of detection (LOD) was calculated 
to be 65 cells according to the fitting curve based on an S/N ratio of 
3, which is lower than the LOD of an AuNPs-based assay 
platform whose LOD was 81 cells.38 The fluorescence of a 
random sequenced ssDNA labelled with FAM (FAM-R) was also 
quenched by BPNSs (Fig 5c black line); however, it was not 
restored by MCF7 cells (Fig 5c, blue line). The shape of the 
saturation curve of AptM/MUC1 (Fig 5b) binding was different 
from that of AptER/ER (Fig 3b) binding, suggesting the 
dissociation constants (Kd) were different. The capabilities of 
three types of breast cancer cell to restore the fluorescence of 
FAM were compared as shown in Fig 5d. Clearly, only MCF7 cells 
completely restored the fluorescence to the level of pure FAM-
AptM (blue bar in Fig 5d); 
 
Fig 5. MCF7 cells efficiently restored the fluorescence. (a) 
Fluorescence recovery in the presence of different numbers of 
MCF7 cells as indicated; (b) The calibration curve of linear 
relationship between MCF7 cell number and recovered 
fluorescence intensity; (c) MCF7 cells failed to recover the 
fluorescence of FAM labelled on a random sequence DNA (FAM-
R, 50nM); (d) Normalized fluorescence recovery of FAM by 
different type of cells (cell number=10000).CFAM-AptM=50nM, 
CBP=0.25mg/mL, λex=470nm. 
 
 
while T47D (aqua bar) and MDA-MB-231 (purple bar) cells failed 
to restore the fluorescence. This clearly indicated the high 
specificity of the aptamer toward MCF7 cells. To confirm the 
results, MCF7 cells were incubated with BPNSs/FAM-AptM 
complex for 2h and imaged using LSCM.  Most MCF7 cells were 
stained with FAM-AptM on the cell surface (Fig 6), which is 
consistent with the fact that AptM aptamer is a specific surface 
marker of MCF7 cell. In contrast, neither T47D nor MDA-MB-
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231 cells were stained with FAM-AptM, which was consistent 
with the spectrofluorometric data.  
  
Fig 6. LSCM images of BPNSs-FAM-AptM treated cells. Cells 
were incubated with BPNSs-FAM-AptM nanoconstructs for 2h, 
then washed with PBS and imaged by LSCM. Cell number = 
10000, CFAM-AptM=50nM, CBP=0.25mg/mL，λex=488nm.  
 
The sensing parameters of our assay and published data in 
the area of tumour cell detection using fluorescence off-on 
switch were summarized in Table 1. The selectivity, detection 
limit and response time of our proposed sensing platform were 
ranked on the top. 
Precise and simultaneous recognition of multiple 
types of breast cancer cells 
Attempting to discriminate breast cancer cells via a single 
aptamer/BPNSs approach that only recognizes a single cell 
surface marker is intrinsically a one-dimensional approach, and 
it will not encounter the need of precise detection. As showed 
above, BPNSs/Cy3-AptER nanoconstruct not only recognized 
MCF7 cells, also recognized T47D cells. In addition, probes with 
single recognising event is often related with false-positive 
results, to some extent, due to low specificity of a aptamer. It 
would be a significant improvement if multiple aptamers could 
be used to combinatorially detect multiple cell surface 
characters since one kind of tumour cell may express a variety 
of tumour markers.30, 31 Such multi-aptamer approaches would 
take full advantage of the capabilities of a cell-based therapy, as 
cells usually integrate multiple inputs to modulate their natural 
decisions in sophisticated ways. 
To this end, we investigated dual aptamer-BPNSs 
nanoconstruct for precise recognition. 100nM Cy3-AptER and 
50nM FAM-AptM were mixed with 0.4 mg/mL of BPNSs in one-
pot as illustrated in scheme 1. At these concentrations, BPNSs 
quenched >90% of the fluorescence of both Cy3 and FAM. The 
resulted mixture showed very low level of Cy3 and FAM 
emission (Fig 7a, black lines). The mixture was incubated with a 
panel of breast cancer cells including MCF7, T47D and MDA-MB-
231, respectively. Following incubation for 2h, fluorescence was 
measured. MCF7 cells showed dual fluorescent emission at 
520nm and 570nm (Fig 7a, aqua lines), indicating simultaneous 
dual restoration of FAM and Cy3. In the case of T47D cells (Fig 
7a, green lines), 68.7% of Cy3 fluorescence was recovered while 
FAM fluorescence was hardly restored. Whereas for MDA-MB-
231 cells (Fig 7a, purple lines), neither FAM nor Cy3 
fluorescence was restored. The dual sensing results were 
plotted in a heat map as shown in Fig 7(b). Obviously, three 
types of breast cancer showed distinct readouts from the 
duplexed assay. The assay results provided valuable information 
in discriminating different type of cells. 
The most precisely identified cell line via this assay was 
MCF7. MCF7 is a widely studied in vitro model for breast cancer. 
The MCF7 cell line has functional estrogen receptors (ER) and is 
dependent on estrogen for growth. Thus, onset and progression 
of human breast cancer is dependent upon ovarian estrogens. 
For this type of cancer, hormone treatment, e.g. anti-estrogen 
treatment (drug tamoxifen and benzothiophene), would result 
in high treatment efficiency. Clearly, accurate identification of 
MCF7 cells would provide vital guidance for the subsequent 
therapy. T47D cells were identified as ER+, which is consistent 
with published data. It would be more accurate if the assay 
could incorporate another T47D-specific aptamer to further 
confirm the molecular trait of T47D.  
In this assay, we used well characterized subtypes of breast 
cancer cells, the resulted data were in good consistence with 
  
 
Materials Probe Target episode Target cells LOD Linear range Response 
time 
ref 
BPNS Aptamer MUC1 
ER 
MCF7 
MCF7, T47D 
65cells 0-2000cells 0-30min  
AuNP Aptamer MUC1 MCF7 81cells 200-12000cells 180min 38 
GO/AuNWs  sDNA miRNA-21 MCF7 NA NA 14h 39 
GO-based Aptamer PTK CCRF-CEM 25cells 
mL-1 
25-25000cells 
mL-1 
20min 40 
GO Aptamer cell SMMC-7721 200cells NA 30min 41 
GO Aptamer 
Sgc8 
cell CCRF-CEM 10cells 100-1×107cells 30min 42 
sDNA Aptamer MUC1 A549 10cells 
mL-1 
10-1000cells mL-
1 
45min 43 
Table 1. comparison of sensing parameters of various methods 
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Fig 7. Duplexed assay of breast cancer cell discrimination via 
BPNSs-Aptamers nanoconstruct. (a) BPNSs/FAM-AptM/Cy3-
AptER nanoconstruct was incubated with various cell lines 
(15000 cells each) for 2h, then fluorescence was measured. 
CFAM-AptM=50nM, CCy3-AptER=100nM, CBP=0.4mg/mL, λex-
FAM=488nm, λex-Cy3=500nm. (b) Heat map showing the 
differential expression of dual tumour markers in various breast 
cancer cell lines shown as FAM and Cy3 intensity, respectively. 
the distinguishing features of the tested cell lines, indicating the 
proposed assay is reliable for cell identification. 
Conclusions 
In summary, with an aim to better characterize breast 
cancer subtypes in a quick, sensitive, and quantitative way, we 
have developed a duplexed assay that is capable of 
simultaneously label-free detection of two tumour markers 
within one run. Our proposed assay involved the use of an 
efficient nanoquencher (BPNSs) and two fluorescently labelled 
aptamers with specific recognition. We demonstrated that our 
setup was capable of precisely discriminating three breast 
cancer subtypes. Currently, the most commonly used technique 
for cell-based analysis is flow cytometry. It is expensive and 
requires large number of cells, tedious sample preparation and 
complex data analysis. Our proposed setup can be measured as 
a facile and cost-effective alternative for quick pre-screen of 
cells. Such setup offered distinct benefits: (i) multiplexed 
biomarker detection could be achieved via incorporating 
multiple specific aptamers in the setup. Nevertheless, it is worth 
noting that, due to the broad emission of a fluorescent dye that 
may result in spectral overlap, fluorophores used for labelling 
should be carefully selected. (ii) easy interpretation of detection 
outcomes without the need for further data processing; (iii) 
applicable to clinical samples such as tissue biopsy specimens 
and blood samples. The combination of BPNSs and aptamers 
shows great potential as a cancer screening platform for 
multiplexed tumour cell subtyping. In addition, the large surface 
area and high bio-compatibility of BPNSs make this material an 
excellent aptamer carrier for the assay.  
The implementation of the current work would lay 
important foundation for future applications, especially in the 
field of circulating tumour cell capturing and simultaneous 
detection. The non-fluorescent BPNSs-Aptamers complex can 
be immobilized to a microfluidic device, for instance, 
microfluidic chips or micro-structured optical fibres, to achieve 
capturing and identification of tumour cells simultaneously. 
Besides the detection of tumour cells, the proposed assay could 
be readily adopted for the multiple detection of other 
oncogenic biomarkers such as RNA, DNA, single nucleotide 
variants (SNVs) or DNA methylation by changing the aptamer 
sequences. Although, in this assay, well-characterized breast 
cancer cells were used, it holds great potential in clinic to 
identify unknown type of cells with distinct character. Hence, 
we believe the present demonstration and promise of our 
proposed assay hold great potential for breast cancer cell 
subtyping and personalized therapy. 
 
 
Experimental 
Materials and reagents 
The fluorescent aptamers FAM-AptM (5’-GGC TAT AGC ACA 
TGG GTA AAA CGA C-FAM), 48Cy3-AptER (Cy3-GGG GUC AAG 
GUG ACC CC-3’),49 Cy3-R (Cy3-AUCGUGUGCUGCUACGA-3’) and 
FAM-R (5’-TCA AAG CAT TCA GTC GAG AT-FAM) were purchased 
from Beijing Sunbiotech Co. Ltd (Beijing, China). All Materials 
and reagents were of biotechnology grade and used without 
further purification. Ultrapure water with an electrical 
resistance 18 MΩ cm-1 was used in all the experiments. 
Preparation and characterization of BPNSs 
BPNSs preparation details and TEM, AFM, Raman details. The 
BPNSs were prepared using the liquid exfoliation technique. 
Particularly, 20 mg of the BP powder was dispersed in 40 mL of 
ultrapure water. Then the mixture solution was sonicated in ice 
water with a sonic tip for 3h (On/Off cycle: 5s/2s, power: 300w, 
frequency: 20 KHz), followed by bath sonication for 5 hours 
(ddH2O) on ice. The ice water was utilized to keep a relatively 
low temperature of the system. Finally, the supernatant was 
collected after centrifuged the dark brown suspension at 5000 
rpm for 1.5h to remove the residual unexfoliated particles. 
Before use, the prepared BPNSs were sonicated in ice water 
with a sonic tip for 5min (On/Off cycle: 5s/2s, power: 300w, 
frequency: 20 KHz) to avoid reunion. The morphology and size 
of as-prepared BPNSs were characterized with a JEM-2100 
transmission electron microscopy (TEM) at 200 kV on a carbon-
coated copper grid and an atom force microscopy (AFM) (MI, 
USA). The horizontal size and height distributions of BPNSs were 
estimated based on statistical analysis TEM and AFM images by 
Nanomeasurer 1.2. Raman spectra of BPNSs was performed on 
a high-resolution confocal Raman microscope at room 
temperature.  
 
Cell culturing  
Breast cancer cell lines MCF7, MDA-MB-231 and T47D were 
purchased from the American Type Culture Collection (ATCC). 
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All cell lines were cultured in a DMEM medium (Thermo 
Scientific) with 10% FBS, 1% penicillin and 1% streptomycin in 
an incubator with 5% CO2 and 88% humidity at 37 °C. Healthy, 
stable cells in logarithmic growth phase were used for all 
experiments. To count the number of cells, we use CountessTM 
automated cell counter (Invitrogen, Korea).  
Fluorescent measurement 
FAM-AptM (final concentration 50nM) was mixed with different 
concentrations BP nanoquencher ranging from 0 to 0.35mg/ml. 
PBS solution was supplemented to make the final solution 
volume to be 100μL. Then, fluorescent intensity was measured 
on a spectrophotometer (Berthold Technologies GmbH & Co.KG, 
Germany) with the excitation of 470 nm. For cell detection, 
BPNSs was mixed with FAM-AptM for 5mins (BP-FAM-AptM, 
CBP=0.25 mg/mL, CFAM-AptM=50nM) and then BP-FAM-AptM 
was incubated with an increasing count of target cells (2500, 
5000, 8000, 10000, 15000, 20000) for 2h in dark. After rinsing 
with PBS buffer for twice, the fluorescence intensity was 
measured. All the fluorescence intensities were recorded using 
the same method. 
Laser scanning confocal microscope (LSCM) analysis 
Breast cancer cell lines were cultured in 96-well plate with 
1×104 per well to adhere for 6h. Then added the BP-FAM-AptM 
mixture (CBP=0.25mg/mL, CFAM-AptM=50nM, reaction fully) 
to MCF7 cells for 2h. After rinsing with PBS buffer, the 96-well 
plate was mosaicked and images of the samples were acquired 
at 488 nm light excitation on a laser scanning confocal platform 
(Leica TCS SP8). The LSCM data were processed with the Leica 
Application Suite AF software. 
Time-resolved fluorescence measurement (lifetime 
determination) 
Lifetime was measured and fitted by a fluorescence lifetime 
imaging microscope. Manufactured based on Olympus FV1200 
and PicoQuant LSM upgrade Kit. 488nm pulsed laser was used 
to excite the fluorescence of BP-FAM, the repetition frequency 
was 40MHz and the output power was 264.1 nW. The signal was 
collected within the range of 500-560 nm. 
Statistical Analyses 
Each experiment was repeated three times. The data were 
processed using the Origin9.0 software. Data were presented as 
Mean ± SD. 
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